Tracking 11 major cities to assess internationality, the index provides data-driven insights to shape urban policy, guide business strategy, and encourage regional exchange
HONG KONG SAR – Media OutReach Newswire – 5 October 2026 – The Hong Kong General Chamber of Commerce (HKGCC) and independent research firm Ipsos launched the second edition of the Asian Cities Internationality Index (ACII), a comprehensive evaluation of 11 major hubs across seven core dimensions. By assessing cities on Business and Economy, Quality of Life, Infrastructure and Connectivity, Innovation and Ideas, Human Capital Diversity, Cultural Interaction, and Government and Legal System for Business, the multifaceted index equips policymakers and business leaders with actionable strategies to elevate Asia’s standing in the global economy.
This year, Hong Kong continued to be Asia’s top international city and the region’s premier gateway for regional and global operations. Out of a maximum score of 100, Hong Kong ranked first with 74.6 (up from 73.7 in 2025), followed by Singapore and Seoul. Elsewhere across the region, Tokyo adjusted to fourth, while Shanghai retained fifth, leading the region in innovation. Bangkok, Kuala Lumpur and Taipei each demonstrated their distinct strengths, as Mumbai rose to ninth place, representing its growing emergence as a globally oriented business hub. Jakarta and Ho Chi Minh City rounded out the list at 10 and 11 respectively.
“By launching the ACII 2026, HKGCC provides a vital, data-driven tool to understand the shifting competitive landscape in Asia”, said HKGCC Chairman Jacob Kam. “Hong Kong’s top ranking proves our fundamental resilience and underscores that global businesses continue to view the city as the ultimate bridge between East and West. From a broader perspective, the ACII provides the strategic insights necessary for Asian cities to collaborate and complement one another’s strengths, fostering a formidable regional economic cluster.”
The issuer is solely responsible for the content of this announcement.
About Hong Kong General Chamber of Commerce (HKGCC)
For 165 years, the Hong Kong General Chamber of Commerce has been the voice of business, growing together with Hong Kong and the business community. Our mission is to promote, represent and safeguard the interests of the business community in Hong Kong, and at the same time provide support, networks, training and business services to help the business community grow. For more details, please visit www.chamber.org.hk.
Global anniversary campaign marks the first step of the brand’s transformation
SINGAPORE, Oct. 5, 2026 /PRNewswire/ — On the eve of its 63rd anniversary, The Coffee Bean & Tea Leaf® (CBTL) has unveiled a global anniversary campaign, the first milestone in its brand transformation journey. For 63 years, CBTL has brought people together over specialty coffee and tea. Now it’s handing the pen to a new generation of artists and creators to write what’s next.
The Coffee Bean & Tea Leaf® is celebrating 63 years of helping people find their flavor.
At the heart of the refresh are the principles that have guided CBTL from the start: a vision to deliver simply the best coffee and tea experience in every community it serves, and a purpose to help people find their flavor, turning an ordinary day into something a little more special. It builds on what has always set CBTL apart: real craft, made by real people.
That spirit comes to life in a refreshed visual identity that pairs contemporary energy with 63 years of coffee and tea craft. It’s bold, expressive and unmistakably CBTL.
Real people are front and center. The campaign features emerging artists, the CBTL brew crew and customers, each with a story to tell across campaign assets, on- and offline. Across participating markets, it will take shape in different ways, reflecting the culture and communities of each place it touches.
“Turning 63 is a moment to look ahead as much as looking back. We’ve built something lasting on craft and community, and now we’re evolving the brand to matter as much to the next generation as it has to the last. This anniversary is the first step of a bigger transformation, and the start of our next chapter of growth.” – Ken Lingan, Chief Executive Officer, The Coffee Bean & Tea Leaf®
“We’re tuned in to culture and the people driving it, and we’re leaning into our role as a creator brand. Craft and self-expression have been part of who we are for 63 years, and this anniversary is as much about celebrating our past as it is about inviting the next generation to bring their own flavor.” – Anshul Laroia, Global Head of Marketing, The Coffee Bean & Tea Leaf®
The Story Continues, One Drink at a Time.
The 63rd anniversary campaign marks the first step in CBTL’s brand transformation, building on more than six decades of craft, community and heritage. As it unfolds across participating markets, CBTL will continue to invite a new generation to Find Their Flavor.
About The Coffee Bean & Tea Leaf® Headquartered in Asia and a proud member of the Jollibee Group, The Coffee Bean & Tea Leaf® is a modern, global specialty coffee and tea house. With a legacy that began in Southern California in 1963, The Coffee Bean & Tea Leaf® now operates in over 1,200 locations across more than 20 countries. We source the finest coffees and teas from local communities and then handcraft every beverage to bring out the freshest flavors. As the creator of The Original Ice Blended®, we continue to innovate to enable people everywhere to enjoy the classics as well as new flavors, both in our cafés and at home. For more information, visit https://corporate.thecoffeebeanandtealeaf.com.
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care
AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ — Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospective, multicenter randomized controlled trial (RCT) of Symphony™, published in the International Wound Journal.
The study enrolled 143 patients across 10 U.S. sites and found that adding Symphony to standard of care significantly improved healing outcomes for diabetic foot ulcers (DFUs):
55% of DFUs achieved complete wound closure within 12 weeks, compared with 35% receiving standard of care alone (p=0.039).
Mean time to complete wound closure was reduced by 7.8 days: 65.4 days with Symphony plus standard of care, compared with 73.2 days with standard of care alone (p=0.041).
The trial enrolled patients with challenging Wagner Grade 1 or 2 DFUs, ranging from ulcers involving the full thickness of the skin to deeper ulcers extending into ligaments, tendons, joint capsules or deep fascia. Patients were randomly assigned to receive weekly Symphony plus standard of care or standard of care alone, for up to 12 weeks or until complete wound closure.
The findings provide high-quality clinical evidence supporting Symphony’s effectiveness and are expected to support product differentiation, clinical adoption and evolving U.S. reimbursement requirements.
“New technologies and high-quality randomised clinical evidence are essential if we are to continue improving outcomes for patients with diabetic foot ulcers,” said lead investigator Dr David Armstrong. “The Symphony trial demonstrates that combining a novel extracellular matrix bioscaffold with high molecular weight hyaluronic acid can significantly improve wound healing when added to good standard of care. Studies like this help clinicians make informed treatment decisions based on robust evidence.”
“This is a major milestone for Symphony. The study delivered clear, statistically significant results: adding Symphony to standard of care for DFUs increased complete wound closure at 12 weeks to 55%, compared with 35% for standard of care alone, and reduced mean healing time by 7.8 days,” said AROA CEO Brian Ward.
“The multicentre design and involvement of recognised key opinion leaders strengthen the evidence’s credibility and clinical relevance. Amid growing demand from clinicians, payors and reimbursement authorities for robust RCT data, this publication places Symphony among a small group of CAMPs with Level I effectiveness data, strengthening its differentiation and commercial value proposition.”
The full study, A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Full Thickness Wounds of the Foot in People with Diabetes: A Randomized Controlled Trial, is available at https://pubmed.ncbi.nlm.nih.gov/42823610/.
About Symphony™ Symphony is AROA’s Cellular, Acellular and Matrix-like Product (CAMP, or “skin substitute”), combining AROA ECM™ with high molecular weight hyaluronic acid (HMWHA). It is designed to treat hard-to-heal wounds such as DFUs and venous leg ulcers.
HMWHA is a naturally occurring polymer with anti-inflammatory properties and the ability to retain approximately 1,000 times its weight in water, making it well suited to chronic wounds with persistent inflammation and moisture imbalance.
While CAMPs are commonly used to treat DFUs, AROA understands Symphony is the only commercially available product incorporating HMWHA.
About Aroa Biosurgery Aroa Biosurgery Limited (ASX: ARX) is a New Zealand-based soft tissue regeneration company developing and commercializing products to improve healing in complex wounds and soft tissue reconstruction.
Laos appoints Saleumxay Kommasith prime minister and moves Sonexay Siphandone to National Assembly president following Xaysomphone’s death.
Today, Laos has made a major change to its top leadership, appointing former Deputy Prime Minister Saleumxay Kommasith as prime minister and moving outgoing Prime Minister Sonexay Siphandone to the presidency of the National Assembly.
The reshuffle follows the death of National Assembly President Xaysomphone Phomvihane in August at age 69.
Xaysomphone passed on 8 August, according to an official announcement from the Lao People’s Revolutionary Party Central Committee. He had been re-elected as National Assembly president just months earlier, in March, when Laos opened its 10th legislative term.
Sounthone Xayachack, a National Assembly vice president, stepped in as acting president on 18 August after Xaysomphone’s death. The position remained open until lawmakers met on today, 5 October, for the second ordinary session of the 10th Legislature.
Shortly after 8 AM on Monday, Laos’ top leaders apppointed Sonexay to lead the National Assembly and approved Saleumxay as Prime Minister. All 158 lawmakers present voted in favor of Saleumxay.
Ongoing Reshuffles
The changes are the latest in a series of major leadership reshuffles in recent years.
In March 2021, then-Prime Minister Thongloun Sisoulith became state president, replacing Bounnhang Vorachit. Phankham Viphavanh, then vice president, became prime minister, while Xaysomphone was elected National Assembly president, replacing Pany Yathotou, who became a vice president.
In December 2022, Phankham stepped down as prime minister and Sonexay, then deputy prime minister, was elected to replace him.
Laos also reshuffled nine senior government officials in June 2025, including changes at the ministries overseeing finance, education, health, labor, agriculture, and industry and commerce.
After the March 2026 National Assembly elections, the country initially kept the same top leadership. Thongloun was re-elected as president, Sonexay remained prime minister, and Xaysomphone was re-elected as National Assembly president.
The New Leadership
Sonexay, born in 1966, has a background in the military and government administration. He served in the Lao People’s Army’s armored forces before holding senior government positions, including governor of Champasak Province and minister of planning and investment. He became deputy prime minister in 2022 and prime minister later that year.
Saleumxay, born in 1968, built his career in diplomacy and foreign relations. He held several positions at the Ministry of Foreign Affairs, including serving as Laos’ representative to the United Nations. He became foreign minister in 2016 and deputy prime minister in 2022.
The leadership reshuffle is expected to continue over the next few days.
ABU DHABI, UAE and HONG KONG, Oct. 5, 2026 /PRNewswire/ — ICAC Commissioner Mr Woo Ying-ming, leading his delegation, concluded his visit to the United Arab Emirates (UAE), during which the ICAC co-launched the “Integrity Behind Bars: A Guide on Corruption Risk Management in Prison Systems” (“Prison Guide”) with the United Nations Office on Drugs and Crime (UNODC) in the 15th United Nations Congress on Crime Prevention and Criminal Justice in Abu Dhabi.
ICAC and UNODC jointly debut the pioneering Prison Guide, ICAC Commissioner: charting the way for enhancing global prison integrity
In his capacity as ICAC Commissioner and President of the International Association of Anti-Corruption Authorities (IAACA), Mr Woo co-launched the “Prison Guide” with Ms Monica Juma, Executive Director of the UNODC on October 1 in Abu Dhabi. Recalling the journey began over a year ago, Mr Woo noted that “Having served as Commissioner of Correctional Services of Hong Kong, my three-decade experience in prison management enlightened me that prisons are the final line of defence of the justice system. A corrupt prison environment not only endangers the safety of law enforcement officers and inmates but also undermines the rehabilitation of prisoners, thus weakening social stability. Therefore, when the UNODC invited the ICAC to lead this project, I relentlessly accepted the challenge, hoping to enhance prison governance worldwide.”
“With full support from the UNODC and the IAACA, various international experts gathered in Hong Kong last November to exchange experiences, bringing forth this guidebook which is grounded in international standards with flexible framework. I hope the “Prison Guide”, which offers comprehensive guidelines covering prison staff recruitment and training, procurement and financial controls, reporting mechanisms, oversights and inspections, prison intelligence and use of technology, will shed light of integrity on every corner behind the bars, enabling prisoners to turn a new page in life,” Mr Woo added.
Mr Woo remarked that the “Prison Guide” also embarked on the maiden voyage of ICAC’s another international mission. Looking forward, the ICAC planned to co-organise training programmes with the UNODC starting next year for prison administrators, anti-corruption agencies and law enforcement bodies worldwide to share the prolonged partnership and robust achievements between the ICAC and the Correctional Services Department.
Executive Director of UNODC Ms Juma also expressed her gratitude to the ICAC and the IAACA for co-producing the “Prison Guide” with the UNODC, which aimed to nip graft in the bud by offering systematic anti-corruption advice. She called upon the UN member states to adopt the recommendations in the guidebook and encouraged greater international cooperation between prison administrations and anti-corruption bodies. The UNODC stood ready to support member states to apply integrity in their judicial systems.
Meanwhile, Dr Kalwan Kwan Ming-tak, Adjunct Associate Professor of the Department of Sociology of the University of Hong Kong, also joined the delegation to share Hong Kong’s successful prison system. ICAC’s Principal Investigator Ms Bonnie Wong Kar-man also expounded on law enforcement experiences against prison corruption.
The meeting drew participation from experts and representatives of international organisations. Apart from commending the guidebook for offering valuable references, participants were also of the view that social development would be benefited from enhanced prison integrity.
During the visit, Mr Woo also held a bilateral meeting with the UAE Accountability Authority to exchange graft fighting insights and explore future collaborations. The delegation took the opportunity to call on Mr Zhao Liang, Chargé d’Affaires at the Embassy of the People’s Republic of China in the UAE to learn local anti-corruption work. Accompanying Mr Woo to attend the UN Crime Congress are Principal Investigators Ms Bonnie Wong Kar-man and Mr Gary Wong Hon-kit, as well as Chief Corruption Prevention Officer Mr Tony Lau Yip-fung and Chief Academy Officer Mr Karson Li Tsz-hin. The delegation returned to Hong Kong on October 3.
The only known investigational therapy for SBMA in Phase 3 development worldwide
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease)
Following submission of the Phase 3 protocol to the U.S. FDA under AnnJi’s active Investigational New Drug (IND) application, AnnJi will proceed with U.S. site activation for the global Phase 3 ROMA-KD trial
AJ201 has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation in both the U.S. and the European Union
TAIPEI, Oct. 5, 2026 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TPEx: 7754), a clinical-stage drug development company focused on innovative small molecules, today announced that it is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial of AJ201 (rosolutamide) in patients with spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease), a progressive, inherited neuromuscular disease with no FDA-approved treatment.
“For people living with SBMA, the disease is felt in everyday moments: a staircase that becomes harder to climb, a meal that becomes harder to swallow, a voice that becomes harder to use,” said Dr. Wendy Huang, Chairperson and CEO of AnnJi. “It affects whole families, often across generations, and there is still no FDA-approved treatment. Advancing AJ201 into Phase 3 brings us one step closer to potentially changing that. We are now focused on activating U.S. trial sites, enrolling patients and completing this study as efficiently and responsibly as possible, with patients and families at our side.”
AJ201 is an investigational oral small molecule that promotes clearance of the pathogenic mutant androgen receptor (mAR) protein and activates cellular stress-response pathways, including Nrf1, Nrf2 and HSF1. A potential first-in-class treatment for SBMA, AJ201 has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA, as well as Orphan Drug Designation in the European Union.
The Phase 3 program builds on encouraging results from the completed Phase 2 study of AJ201, announced in May 2025, and was informed by subsequent interactions with regulatory authorities.
The ROMA-KD trial is a global, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of AJ201 in ambulatory individuals with symptomatic SBMA. Approximately 200 patients are expected to enroll globally, with the United States as a key region. The trial is intended to support potential global regulatory submissions for AJ201. AnnJi will coordinate site activation across regions in line with its global development and partnering strategy.
Patient and Care Partner Advisory Council
AnnJi has established its SBMA Patient and Care Partner Advisory Council, first announced in collaboration with the Kennedy’s Disease Association (KDA) at the 2026 KDA International Patient and Scientific Conference. The Council brings together people living with SBMA and their care partners, whose lived experience offers insights that clinical data alone cannot capture.
Serving in an advisory capacity, the Council provides a structured forum for ongoing, two-way dialogue between AnnJi and the SBMA community. Members share perspectives that may help inform AnnJi’s patient-centered research and clinical development, including considerations for study design and the development of clear, accessible patient-facing materials. The Council operates independently of AnnJi’s clinical trials, and participation has no bearing on trial eligibility or enrollment.
Commitment to the SBMA Community
AnnJi remains committed to advancing AJ201 for people living with SBMA and their families, and to working in transparent partnership with patients, care partners, clinicians and advocacy organizations worldwide.
About SBMA and AJ201
SBMA, or Kennedy’s disease, is a rare, X-linked inherited neuromuscular disorder caused by a CAG repeat expansion in the androgen receptor (AR) gene. The resulting mutant AR protein contributes to motor neuron and muscle degeneration through mechanisms involving cellular toxicity, oxidative stress and neuroinflammation. SBMA is believed to be substantially underdiagnosed, in part because its symptoms are often mistaken for other neuromuscular conditions, such as amyotrophic lateral sclerosis (ALS), and because the absence of an approved treatment has offered little incentive for genetic testing. There is currently no FDA-approved treatment for SBMA.
AJ201 (rosolutamide; also known as JM17) is an investigational oral small molecule designed to address multiple disease mechanisms implicated in SBMA. AJ201 promotes clearance of the pathogenic mutant AR protein and activates cellular pathways involved in antioxidant defense, protein quality control and stress response, including Nrf1, Nrf2 and HSF1.1 Through these complementary mechanisms, AJ201 is being developed as a potential disease-modifying therapy for SBMA.
1 Bott LC, et al. Hum Mol Genet. 2016.
About AnnJi Pharmaceutical
AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754) is a clinical-stage drug development company focused on innovative new chemical entities (NCEs) for diseases with high unmet medical need in neurology, dermatology and immune-inflammatory conditions. Its pipeline includes AJ201 for Kennedy’s disease (SBMA), a rare neuromuscular disease, as well as HDAC6-targeted programs in neuropathy, including chemotherapy-induced peripheral neuropathy, and fibrotic diseases.
AnnJi is committed to developing differentiated therapies that improve the quality of life of patients with neglected chronic diseases. The company advances high-quality drug candidates through clinical proof of concept and collaborates with global pharmaceutical partners on further development and commercialization, with the goal of bringing its therapies to patients worldwide and driving sustainable growth.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the timing, conduct and potential outcomes of the Phase 3 ROMA-KD trial, site activation and enrollment, the regulatory pathway for AJ201, and AnnJi’s development and partnering plans. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify such statements. These statements are based on management’s current expectations and are subject to risks and uncertainties, including clinical, regulatory, manufacturing, partnering, financing and operational risks, that could cause actual results to differ materially. Additional information about these risks is available in AnnJi’s disclosures filed with the Taipei Exchange and published on the Market Observation Post System (MOPS). AJ201 is an investigational product and has not been approved by any regulatory authority for any indication. Forward-looking statements speak only as of the date of this press release, and, except as required by applicable law, AnnJi undertakes no obligation to update them.
HONG KONG SAR – Media OutReach Newswire – 5 October 2026 – NAMAA has announced the launch of Future Foods and Picnic, two new ventures that support restaurants, businesses and consumers across the Middle East. Together, they strengthen NAMAA’s portfolio of digital food solutions, helping restaurant operators grow their delivery business while making workplace dining simpler.
Future Foods Opens New Revenue Opportunities for Restaurant Operators
Born out of the Kitchens business, Future Foods was created to help restaurant operators generate additional revenue through virtual delivery brands. Today, it is the largest virtual brand company in the restaurant space, with more than 1,500 live locations.
The Future Foods model allows restaurants to launch established delivery brands from their existing kitchens without investing in another location or major infrastructure. With their existing kitchens, operators can optimise food costs, reach more customers and increase delivery sales.
Future Foods also provides support with storefront setup, delivery platform integration, marketing and operations, allowing restaurant teams to focus on preparing great food while strengthening their delivery business.
Restaurant partners can choose from a portfolio of nationally recognised brands across a range of cuisines, including Pasta Glory, Brooklyn Calzones, Sunny & Fine’s, Poke Picnic and Brekkie Bagels, fulfilling customer demand in the market.
Picnic Brings a Simpler Workplace Dining Experience
Alongside Future Foods, NAMAA has introduced Picnic, a workplace dining platform built around the idea of “food at work, simplified.” By combining CloudKitchens with local brick-and-mortar restaurants, Picnic gives employees a wide variety of lunch options through a digital food court experience.
Orders are delivered to a designated Picnic shelf on each office floor within a 20 to 30-minute delivery window, making lunchtime easier while reducing the need to manage individual food deliveries.
Picnic also offers a more cost-effective approach to workplace dining. With no delivery fees, tips, administrative charges, nor minimum order requirements, both employers and employees benefit from greater convenience at no extra cost.
The platform offers flexible corporate solutions, including subsidised lunch programmes, non-subsidised daily deliveries, group ordering and fee-free catering for larger corporate events, allowing businesses to tailor to their employees’ needs.
Together, Future Foods and Picnic reflect NAMAA’s commitment to supporting restaurant growth while making workplace dining easier. As food delivery continues to evolve across the Middle East, both platforms give restaurants, businesses and consumers more flexibility and choice.
Hashtag: #NAMAA
The issuer is solely responsible for the content of this announcement.
About NAMAA
NAMAA is a leader in driving the growth of digital food solutions, quick commerce, and the underlying real estate foundations. The founding members have been laying the groundwork since 2019, guided by a philosophy centred on developing infrastructures that give consumers fast and dependable access to meals, groceries, and essentials. Part of the wider ATOMS Group, the company has since grown into a multi-sector network with operations spanning the Middle East.
HONG KONG SAR – Media OutReach Newswire – 5 October 2026 – Amid rising operating costs and accelerating digital transformation, many small and medium-sized enterprises (SMEs) in Hong Kong are facing increasing pressure from equipment investment, limited manpower resources, and the growing complexity of print management across multiple departments. For organizations with multiple teams, office locations, or hybrid work arrangements, maintaining a reliable and efficient printing environment at a reasonable cost has become an important operational challenge.
Most businesses primarily print A4 documents such as contracts, invoices, reports, and administrative paperwork. When A4 printing is sufficient to meet the majority of daily business requirements, investing in larger and more expensive printing equipment may not be necessary. Brother’s Managed Print Service (MPS) allows businesses to flexibly deploy printing resources according to actual operational needs without incurring substantial upfront capital expenditure. The service also provides comprehensive consumables management, maintenance, and professional technical support, making print management simpler and more efficient.
Comprehensive Print Management That Reduces Administrative and IT Workloads
Traditional printer ownership often involves purchasing equipment, replenishing consumables, arranging repairs, and managing technical support, all of which can increase administrative efforts and hidden operating costs, particularly for SMEs without dedicated IT or administrative teams.
Brother’s Managed Print Service includes printer usage, consumables supply, maintenance services, and technical support. This enables businesses to enjoy a reliable printing experience without spending additional time managing day-to-day printing operations, allowing resources to be redirected toward core business development.
Eliminate Large Capital Expenditure and Improve Cash Flow Management
For growing businesses and startups, major investments in office equipment can significantly impact cash flow planning.
Under the monthly subscription model, businesses pay a fixed monthly fee to access professional-grade Brother printing equipment without making a substantial upfront investment. The service also does not impose a fixed monthly print volume limit, enabling organizations to adjust printing usage and device deployment according to operational needs. This flexibility helps businesses control costs more effectively while minimizing resource underutilization and wastage. Flexible Multi-Device Deployment for Greater Departmental Productivity
For organizations with multiple departments or work teams, relying on a single shared printer can often result in wait times and reduced document processing efficiency.
Brother’s Managed Print Service solution enables businesses to deploy multiple printers according to actual operational requirements. For example, administrative, human resources, finance, and sales departments can each be equipped with printers tailored to their specific needs. This helps minimize waiting time, reduce cross-department disruptions, improve workflow efficiency, and enhance document confidentiality.
The solution is also well-suited for organizations with multiple offices, retail outlets, or distributed business teams, providing centralized management of multiple devices while ensuring consistent technical support and after-sales service.
Proactive Consumables Replenishment Minimizes Business Disruptions
Many businesses have experienced workflow interruptions caused by depleted toner or consumables, potentially delaying important document production, customer service, and internal operations.
Brother’s Managed Print Service automatically monitors printer performance and consumables usage, proactively arranging replenishment before supplies run low. For industries with high printing demands, such as insurance, financial services, logistics, professional services, and education, this not only reduces administrative workload but also minimizes inventory management and procurement-related tasks.
Designed for Hong Kong Offices and Hybrid Work Environments
As hybrid working becomes increasingly common, businesses require more flexible approaches to printer deployment.
Brother offers a range of compact yet feature-rich printers that are particularly suitable for Hong Kong’s space-constrained office environments, departmental workspaces, and shared offices. With a smaller footprint while still meeting everyday business printing requirements, these devices help organizations make better use of valuable office space.
In addition, Brother provides remote technical support services to assist with device setup, network connectivity, and other technical issues, reducing the day-to-day support burden on IT teams.
Five Key Benefits of Choosing Brother “Managed Print Service”
Reduce large upfront procurement costs and adapt flexibly to changing business needs
Proactive consumables replenishment to minimize inventory management and purchasing efforts
Maintenance and professional technical support to reduce equipment downtime risks
Automated usage monitoring to lower administrative and management workload
Compact printer design ideal for Hong Kong’s limited office space
Focus on Growing Your Core Business
Through its monthly subscription model, flexible device deployment, automated consumables management, and professional technical support, Brother’s Managed Print Service helps businesses simplify print management, reduce overall operating costs, and improve productivity across departments and locations.
When most printing requirements consist primarily of A4 documents, businesses can select the most suitable device configuration based on their actual operational needs without allocating additional resources to infrequent printing demands. By adopting a more flexible and streamlined print management approach, organizations can focus on growing their business, serving customers, and driving innovation, ultimately strengthening their competitive advantage.
Information contained in this release is accurate at the time of publication and is subject to change without prior notice. Hashtag: #BrotherHK #BrotherMPS #BusinessSolutions #OfficeSolutions #PrintManagement #PrinterRental #OfficeSolutions #Sustainability
The issuer is solely responsible for the content of this announcement.
About Brother International (HK) Limited
Founded in Japan in 1908, Brother has over 110 years of history. It has developed into an international brand with 16 production facilities and 51 sales points worldwide, spanning 44 countries. Brother produces high-quality and innovative products for the printing and imaging, labelling, and sewing markets, maintaining a leading position in the industry. Its main products include a variety of inkjet and laser printers, multifunction printers, fax machines, scanners, label printers, and a range of home sewing machines and commercial embroidery machines.
As a trusted brand, Brother adheres to a “customer-first” philosophy in all aspects of its business, continually meeting diverse customer needs and market challenges with comprehensive and high-quality solutions.
Brother International (Hong Kong) is one of the leading suppliers of home, office, and industrial products in Hong Kong. Established in 1994, it has been serving customers in Hong Kong and Macau for over 30 years. According to IDC’s Global Hardware Peripheral Tracker report, Brother’s A3 multifunction colour inkjet printer has been the number one in shipment volume in the world for 18 consecutive years from 2008 to 2025, reaffirming Brother’s business success in the region.
For more information about Brother Hong Kong, contact our WhatsApp at (852) 3187 0505 or visit the website www.brother.com.hk。
NOTE: All brand and products names are trademarks or registered trademarks of their respective companies.
www.chamber.org.hk. 
https://www.brother.com.hk
https://www.facebook.com/brother.hk/?locale=zh_HK
https://www.instagram.com/brother_hongkong/?hl=en
